ASH 2016: A Clinical Overview of JAK Inhibitor Therapeutics for the Management of Patients with Polycythemia Vera

http://academiccme.com/wp-content/uploads/2017/02/ASH-Image--wpcf_400x400.jpg

Course Information

Therapautic Area: Hematology
Format(s): Downloadable Transcript , Post Conference Review and Analysis
Credit(s): 1.00 AMA PRA Category 1 Credit(s)™
Activity Dates: February 9, 2017 to February 8, 2018

 

Program Overview

This CME program will highlight recent scientific advances in the treatment and management of patients with polycythemia vera (PV) presented at the American Society of Hematology 58th Annual Meeting & Exposition in San Diego, California. Three expert faculty will discuss predictors of PV as well as strategies for early diagnosis and initiation of treatment. Recent clinical trial data, particularly that of current and emerging JAK inhibitors, will be analyzed. Faculty will relay optimal methods for educating newly diagnosed patients and address barriers that may affect clinical outcomes. At the conclusion of this discussion-based activity, learners will be better acquainted with optimal monitoring and management techniques for patients with polycythemia vera.

Target Audience

Oncologists/hematologists, and other healthcare professionals responsible for the diagnosis, treatment or management of patients with PV.

Learning Objectives

  1. Review the diagnostic criteria of polycythemia vera, including risk stratification and managing treatment-intolerant special patient populations.
  2. Analyze clinical trial data of current and emerging JAK inhibitors for the treatment of polycythemia vera presented at ASH 2016.
  3. Incorporate recent science to optimally address patient-specific treatment barriers to improve outcomes for patients with polycythemia vera.

Faculty

Mesa Headshot_ASH PCRARuben A. Mesa, MD
Professor of Medicine
Chair, Division of Hematology & Medical Oncology
Deputy Director, Mayo Clinic Cancer Center
Chair, Arizona Cancer Coalition
Phoenix, Arizona

 

Noel Headshot_ASH PCRAPierre Noel, MD
Professor of Medicine
Director, Blood & Bone Marrow Transplant
Mayo Clinic Cancer Center
Phoenix, Arizona

 

Palmer Headshot_ASH PCRAJeanne M. Palmer, MD
Division of Hematology & Medical Oncology
Mayo Clinic Cancer Center
Phoenix, Arizona

 

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Relationship Identified With:
Ruben A. Mesa, MD Consultant/Advisor: AOP Orphan Pharmaceuticals AG; ARIAD Pharmaceuticals, Inc.; Novartis Pharmaceuticals CorporationGrant/Research Support: CTI BioPharma Corp.; Gilead Sciences, Inc.; Incyte Corporation; Promedior, Inc.
Pierre Noel, MD Consultant/Advisor: Blood Systems, Inc.; Entegrion, Inc.
Jeanne M. Palmer, MD Nothing to disclose.

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Emma Gilmartin; Nicole Brestowski  and Sara Lee hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Incyte Corporation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Incyte Corporation do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact admin@academiccme.com.

BUTTON


Provided by AcademicCME AcademicCME Logo

This CME activity has been supported by an independent educational grant from Incyte Corporation.